Eisai Co., Ltd.
【Eisai】Anti-Amyloid β Antibody Sales of ¥29.3 Billion｜Q1 2026
Eisai’s anti-Amyloid β antibody "Leqemba®" generated sales revenue of ¥29.3 billion in Q1 2026, an increase from ¥23.1 billion in the same period last year. Key sales performances are shown in the US, Japan, and China. The product is being co-commercialized with Biogen.
Key Figures
- Sales Revenue: ¥29.3 billion (YoY +¥6.2 billion)
- US Sales: ¥15.4 billion (YoY +¥6.3 billion)
- Japan Sales: ¥6.1 billion (YoY +¥0.6 billion)
AI要約
Performance Overview
Eisai announced that its anti-Amyloid β antibody "Leqemba®" achieved sales revenue of ¥29.3 billion in Q1 2026. This represents an increase from ¥23.1 billion in the same period last year and demonstrates sales in key countries including the US, Japan, and China. The US sales reached ¥15.4 billion, the highest figure, with an increase compared to the same period last year. In China, sales were ¥4.8 billion, affected by inventory adjustments. The product is scheduled for joint commercialization and promotion with Biogen.
Future Outlook and Impact for Investors
Eisai plans to lead development and regulatory submissions globally, advancing joint commercialization with Biogen. With expected sales growth in 2026, there is optimism about expanding the anti-Amyloid β antibody market. Detailed financial results will be announced at the earnings release scheduled for August 3, 2026. For investors, progress in clinical trials and commercialization, along with long-term growth potential, are points of focus.
Eisai Co., Ltd.
Company overview · Stock price · Financial data · All IR
